Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;143(1):190-200.e20.
doi: 10.1016/j.jaci.2018.08.031. Epub 2018 Sep 8.

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

William Busse  1 , Geoffrey Chupp  2 , Hiroyuki Nagase  3 , Frank C Albers  4 , Scott Doyle  5 , Qin Shen  6 , Daniel J Bratton  7 , Necdet B Gunsoy  5
Affiliations
Free article
Review

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

William Busse et al. J Allergy Clin Immunol. 2019 Jan.
Free article

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] J Allergy Clin Immunol. 2019 Jun;143(6):2336. doi: 10.1016/j.jaci.2019.04.010. J Allergy Clin Immunol. 2019. PMID: 31176383 No abstract available.

Abstract

Background: Three anti-IL-5 pathway-directed therapies are approved for use in patients with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are available.

Objective: We sought to compare the efficacy of licensed doses of mepolizumab, benralizumab, and reslizumab in patients with SEA, according to baseline blood eosinophil counts.

Methods: This indirect treatment comparison (ITC) used data from a Cochrane review and independent searches. Eligible studies were randomized controlled trials in patients aged 12 years or greater with SEA. End points included annualized rate of clinically significant exacerbations and change from baseline in Asthma Control Questionnaire score and FEV1. An ITC was performed in patients with Asthma Control Questionnaire scores of 1.5 or greater and stratified by baseline blood eosinophil count.

Results: Eleven studies were included. All treatments significantly reduced the rate of clinically significant exacerbations and improved asthma control versus placebo in all blood eosinophil count subgroups. Mepolizumab reduced clinically significant exacerbations by 34% to 45% versus benralizumab across subgroups (rate ratio ≥400 cells/μL: 0.55 [95% CI, 0.35-0.87]; ≥300 cells/μL: 0.61 [95% CI, 0.37-0.99]; and ≥150 cells/μL: 0.66 [95% CI, 0.49-0.89]; all P < .05) and by 45% versus reslizumab in the 400 cells/μL or greater subgroup (rate ratio, 0.55 [95% CI, 0.36-0.85]; P = .007). Asthma control was significantly improved with mepolizumab versus benralizumab (all subgroups: P < .05) and versus reslizumab in the 400 cells/μL or greater subgroup (P = .004). Benralizumab significantly improved lung function versus reslizumab in the 400 cells/μL or greater subgroup (P = .025).

Conclusions: This ITC of the licensed doses suggests that mepolizumab was associated with significantly greater improvements in clinically significant exacerbations and asthma control compared with reslizumab or benralizumab in patients with similar blood eosinophil counts.

Keywords: Benralizumab; indirect treatment comparison; mepolizumab; network meta-analysis; reslizumab; severe eosinophilic asthma.

PubMed Disclaimer

Comment in

  • Indirect Treatment Comparisons and Biologics.
    Mauger D, Apter AJ. Mauger D, et al. J Allergy Clin Immunol Pract. 2019 Jan;7(1):131-133. doi: 10.1016/j.jaip.2018.11.008. J Allergy Clin Immunol Pract. 2019. PMID: 30598174 No abstract available.
  • Indirect treatment comparisons and biologics.
    Mauger D, Apter AJ. Mauger D, et al. J Allergy Clin Immunol. 2019 Jan;143(1):84-86. doi: 10.1016/j.jaci.2018.11.005. J Allergy Clin Immunol. 2019. PMID: 30612667 No abstract available.
  • Reply.
    Gunsoy NB, Bratton DJ, Albers FC, Busse W. Gunsoy NB, et al. J Allergy Clin Immunol. 2019 Mar;143(3):1267-1268. doi: 10.1016/j.jaci.2018.11.023. Epub 2019 Jan 11. J Allergy Clin Immunol. 2019. PMID: 30639066 No abstract available.
  • Indirect treatment comparison of asthma biologics fraught with methodology issues.
    Bourdin A, Molinari N. Bourdin A, et al. J Allergy Clin Immunol. 2019 Mar;143(3):1266-1267. doi: 10.1016/j.jaci.2018.11.024. Epub 2019 Jan 11. J Allergy Clin Immunol. 2019. PMID: 30639069 No abstract available.